PHA ACE2 amplification
(Die Seite wurde neu angelegt: „{{up|Target ACE2, Spike protein}} {{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}}“) |
|||
| Zeile 2: | Zeile 2: | ||
{{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}} | {{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}} | ||
| + | {{tp|p=32700580|t=2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.|pdf=|usr=014}} | ||
| + | {{tp|p=32729248|t=2020. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.|pdf=|usr=017}} | ||
| + | {{tp|p=32752138|t=2020. Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation.|pdf=|usr=018}} | ||
| + | {{tp|p=32760206|t=2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.|pdf=|usr=018}} | ||
| + | {{tp|p=32928868|t=2020. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.|pdf=|usr=019}} | ||
| + | {{tp|p=33204291|t=2020. Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19.|pdf=|usr=022}} | ||
| + | {{tp|p=33251800|t=2020. A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW).|pdf=|usr=021}} | ||
| + | {{tp|p=32735768|t=2020. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.|pdf=|usr=017}} | ||
| + | {{tp|p=33254514|t=2020. Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19.|pdf=|usr=022}} | ||
Aktuelle Version vom 27. April 2021, 18:27 Uhr
| Target ACE2, Spike protein |
32469114 2020. An update on ACE2 amplification and its therapeutic potential.
32700580 2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.
32729248 2020. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression.
32752138 2020. Tobacco, but Not Nicotine and Flavor-Less Electronic Cigarettes, Induces ACE2 and Immune Dysregulation.
32760206 2020. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
32928868 2020. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.
33204291 2020. Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19.
33251800 2020. A Novel Angiotensin Converting Enzyme 2 (ACE2) Activating Peptide: A Reflection of 10 Years of Research on a Small Peptide Ile-Arg-Trp (IRW).
32735768 2020. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2.
33254514 2020. Nasal lavage containing Angiotensin-Converting Enzyme-2 agonist can prevent and reduce viral load in COVID-19.
